Isolates
|
Recovery of lesion size (%)
|
---|
2016–2017
|
2017–2018
|
Total percent recovery
|
---|
T2 Parent
|
17.82 (24.94)
|
26.46 (30.27)
|
44.28 (41.60)
|
T2 Mutant
|
24.83 (29.30)
|
27.17 (31.35)
|
52.00 (46.11)
|
T3 Parent
|
18.07 (24.46)
|
27.30 (31.23)
|
45.37 (42.31)
|
T3 Mutant
|
25.84 (29.70)
|
30.13 (33.08)
|
55.97 (48.63)
|
T4 Parent
|
25.24 (30.10)
|
30.41 (33.25)
|
55.65 (48.30)
|
T4 Mutant
|
30.97 (33.76)
|
40.29 (39.30)
|
71.26 (57.75)
|
T16 Parent
|
31.45 (34.04)
|
34.36 (35.70)
|
65.82 (54.28)
|
T16 Mutant
|
36.71 37.21
|
46.10 (42.67)
|
82.80 (68.44)
|
T20 Parent
|
36.18 (36.95)
|
43.51 (41.21)
|
79.69 (63.37)
|
T20 Mutant
|
44.45 (41.79)
|
51.38 (45.77)
|
95.67 (75.81)
|
T21 Parent
|
18.16 (23.62)
|
21.63 (27.46)
|
39.79 (38.87)
|
T21 Mutant
|
24.07 (28.73)
|
26.71 (31.35)
|
50.79 (45.43)
|
T25 Parent
|
20.77 (26.93)
|
27.97 (31.84)
|
48.74 (44.26)
|
T25 Mutant
|
26.87 (31.01)
|
32.85 (34.74)
|
59.71 (50.68)
|
T.viride*
|
27.29 (41.47)
|
29.31 (31.98)
|
56.60 (48.86)
|
T.harzianum*
|
17.98 (25.07)
|
20.07 (26.59)
|
38.05 (38.04)
|
Metalaxyl-M+Mancozeb*
|
35.44 (36.43)
|
37.35 (37.63)
|
72.80 (58.78)
|
Control
|
(-)16.50 (23.64)
|
(-)23.41 (23.40)
|
(-)39.91 (39.11)
|
CD (p ≤ 0.05)
|
10.29
|
8.90
|
11.66
|
- T2, T3, T4, T16, T20 and T21 = T. asperellum, T25 = T. harzianum
- *Standard checks
- Figures in parenthesis is arc sine transformation